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1. INTRODUCTION {#cas13562-sec-0001}
===============

Metabolic stress often occurs in rapidly proliferating cells that persistently need more energy for survival and growth.[1](#cas13562-bib-0001){ref-type="ref"}, [2](#cas13562-bib-0002){ref-type="ref"}, [3](#cas13562-bib-0003){ref-type="ref"} Overcoming metabolic stress is certainly a critical step during the growth of solid tumors. A key signaling pathway involved in metabolic adaptation is the LKB1‐AMPK pathway.[4](#cas13562-bib-0004){ref-type="ref"} AMPK functions as a critical sensor of cellular energy status and is activated under energy stress conditions.[5](#cas13562-bib-0005){ref-type="ref"} The underlying mechanisms of cell death and survival under metabolic stress are not well understood. In addition, cancer cells have their own ways to adapt to metabolic deprivation.[6](#cas13562-bib-0006){ref-type="ref"}, [7](#cas13562-bib-0007){ref-type="ref"}, [8](#cas13562-bib-0008){ref-type="ref"} One study reported that nutrient deprivation can induce the Warburg effect, thereby indicating the role of the Warburg effect in helping cancer cells to overcome metabolic stress.[9](#cas13562-bib-0009){ref-type="ref"}

Otto Warburg first discovered that even with normal concentrations of oxygen, cancer cells prefer anaerobic breakdown of glucose over mitochondrial oxidative phosphorylation to generate energy, and this phenomenon is known as the "Warburg effect".[10](#cas13562-bib-0010){ref-type="ref"} The Warburg effect is characterized by enhanced glucose uptake and lactate production, representing one of the most important metabolic transformations accompanying tumorigenesis.[10](#cas13562-bib-0010){ref-type="ref"}

Pim1 is a member of constitutively activated serine/threonine kinases and was first identified as the proviral integration site for Moloney murine leukemia virus, which causes murine leukemia.[11](#cas13562-bib-0011){ref-type="ref"}, [12](#cas13562-bib-0012){ref-type="ref"}, [13](#cas13562-bib-0013){ref-type="ref"} Pim1 can interact with and phosphorylate several targets that are involved in cell cycle progression or apoptosis.[14](#cas13562-bib-0014){ref-type="ref"} It is overexpressed in many types of cancer cells, including hepatocellular cancer, prostate cancer, glioblastoma, lung cancer, breast cancer and CRC, and its overexpression is associated with tumor development and progression.[13](#cas13562-bib-0013){ref-type="ref"}, [15](#cas13562-bib-0015){ref-type="ref"}, [16](#cas13562-bib-0016){ref-type="ref"}, [17](#cas13562-bib-0017){ref-type="ref"}, [18](#cas13562-bib-0018){ref-type="ref"}, [19](#cas13562-bib-0019){ref-type="ref"} In colon cancer, Pim1 repression leads to major changes in oncogenic signal transduction with regard to p21^Cip1/WAF1^, STAT3, JNK, c‐Myc, and survivin and in the levels of apoptosis‐related proteins Puma, Bax, and Bcl‐xL.[19](#cas13562-bib-0019){ref-type="ref"} However, the underlying mechanism of Pim1 in CRC remains unclear.

In the present study, we aimed to address some key questions regarding the expression pattern of Pim1 in CRC. Thus, we carried out a series of in vitro and in vivo experiments to identify the role of Pim1 in CRC progression. We discovered that Pim1 is upregulated by glucose deprivation in CRC through AMPK signaling and that Pim1 overexpression promotes the Warburg effect and consequently facilitates tumor progression.

2. MATERIALS AND METHODS {#cas13562-sec-0002}
========================

2.1. Patients and specimens {#cas13562-sec-0003}
---------------------------

A total of 296 patients who were newly diagnosed with CRC and had undergone surgical resection without any preoperative therapy at FDUSCC between 2008 and 2009 were selected for this retrospective study. Written informed consent was obtained from all patients. All specimens were reviewed by two pathologists to confirm the diagnosis. The pathologists selected representative tumor regions from primary formalin‐fixed paraffin‐embedded (FFPE) blocks. Corresponding fresh tumor tissue samples were obtained from the tissue bank of FDUSCC. This study was conducted in accordance with the Declaration of Helsinki and approved by the institutional review board of FDUSCC.

Data regarding clinicopathological features of CRC patients including age, gender, AJCC stage, tumor differentiation, vascular invasion, Ki‐67 index, TNM stage and differentiation were recorded.

2.2. Immunohistochemistry {#cas13562-sec-0004}
-------------------------

Tissue microarrays (TMA) containing 296 cancer tissues and adjacent normal colorectal epithelial tissues were prepared and incubated with primary antibodies against Pim1 (1:100; Abcam, Cambridge, UK) at 4°C overnight. IHC results were evaluated by two certificated pathologists who were blinded to patient information. Pim1 expression was evaluated and quantified based on the intensity and extent of staining.[20](#cas13562-bib-0020){ref-type="ref"}, [21](#cas13562-bib-0021){ref-type="ref"} Briefly, cytoplasmic and/or nuclear staining of Pim1 was assigned an intensity score (0 \[no staining\], 1 \[weak\], 2 \[moderate\], and 3 \[strong\]) and an extent score (0 \[no staining\], 1 \[\<10% cells\], 2 \[10%‐50% cells\], 3 \[\>50% cells\]). The intensity and extent scores were then added to give a total score ranging from 0 to 6. Cases with scores 0‐2 were considered negative, 3‐4 weakly positive and 5‐6 strongly positive.

2.3. Cell lines and culture conditions {#cas13562-sec-0005}
--------------------------------------

A series of human CRC cell lines (HT29, RKO, SW480, SW620, LOVO, HCT116, SW1116, and Caco2) were purchased from the Cell Bank of Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China). The cell lines were cultured in DMEM (Gibco, Waltham, MA, USA) with 25 mmol/L glucose, 10% FBS (Gibco) and 1% mixture of penicillin and streptomycin in a 5% CO~2~ incubator at 37°C. To induce metabolic stress, cells were cultured in glucose‐free DMEM (Gibco).

2.4. RNA extraction, reverse transcription (RT) and real‐time qPCR {#cas13562-sec-0006}
------------------------------------------------------------------

Total RNA was extracted by TRIzol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer\'s instructions. Then, 500 ng RNA was transcribed into cDNA using the PrimeScript RT reagent kit (Takara, Shiga, Japan). Quantitative real‐time PCR was completed with SYBR Premix Ex Taq II according to the manufacturer\'s protocol (Takara). β‐Actin was used as the internal control to normalize mRNA levels. Relative mRNA level was calculated using the 2^−ΔΔCt^ comparative method. The following primer sequences were used: 5′‐CCCGACAGTTTCGTCCTGAT‐3′ (forward) and 5′‐ACCCGAAGTCGATGAGCTTG‐3′ (reverse) for Pim1; 5′‐ACAGAGCCTCGCCTTTGCCGAT‐3′ (forward) and 5′‐CTTGCACATGCCGGAGCCGTT‐3′ (reverse) for actin; 5′‐GATTTCACCAAGCGTGGACT‐3′ (forward) and 5′‐CCACACCCACTGTCACTTTG‐3′ (reverse) for HK2; and 5′‐CAGCTTGGAGTTTGCAGTTAC‐3′ (forward) and 5′‐TGATGGATCTCCAACATGG‐3′ (reverse) for LDHA.

2.5. Proliferation and colony formation assays {#cas13562-sec-0007}
----------------------------------------------

Cells transfected with vectors or siRNAs were resuspended and seeded in triplicate in 96‐well plates at a density of 5000 cells/well. CCK8 reagent (10 μL; Dojindo, Kumamoto, Japan) was added to each well at 0, 24, 48, 72 and 96 hours. Absorbance was measured at 450 nm after incubation for 2 hours at 37°C. For the colony formation assay, single‐cell suspensions were prepared and seeded into 6‐well plates at a density of 500 cells/well and cultured in complete medium for 14 days. The cell colonies were fixed, stained and then photographed.

2.6. Western blotting {#cas13562-sec-0008}
---------------------

Western blotting was carried out as previously described.[22](#cas13562-bib-0022){ref-type="ref"}

2.7. Glucose uptake and lactate production assays {#cas13562-sec-0009}
-------------------------------------------------

For the glucose uptake assay, CRC cells were transfected with plasmids or siRNAs and incubated for 24 hours. Glucose concentrations in the media were measured using a colorimetric glucose assay kit (BioVision, Milpitas, CA, USA) and normalized according to cell number.[23](#cas13562-bib-0023){ref-type="ref"}

Levels of lactate produced were examined using a Lactate Colorimetric Assay Kit (BioVision). Indicated cells were seeded in 96‐well plates at a density of 5000 cells/well. After incubation for 24 hours, the culture medium was replaced with FBS‐free DMEM. After 8 hours, lactate assays were carried out according to the manufacturer\'s protocol using the culture medium collected from each sample.[24](#cas13562-bib-0024){ref-type="ref"}

2.8. Cancer xenograft models in nude mice {#cas13562-sec-0010}
-----------------------------------------

Animal experiments were carried out according to the Guide for the Care and Use of Laboratory Animals (NIH publication no. 80‐23, revised in 1996) and in compliance with the institutional ethical guidelines. Approximately, 5 × 10^6^ stable CRC cell lines with different Pim1 levels were injected into 6‐week‐old male athymic nude mice. The animals were killed after 4 weeks, and tumors were removed.

2.9. Antibodies and reagents {#cas13562-sec-0011}
----------------------------

The following antibodies were used in this study: anti‐Pim1 (Abcam, Cambridge, UK); anti‐β‐actin (13E5) rabbit mAb (4970; Cell Signaling Technology, Danvers, MA, USA); anti‐AMPKα (D63G4) rabbit mAb (5832S; Cell Signaling Technology); anti‐phospho‐AMPKα (Thr172) (40H9) rabbit mAb (2535S; Cell Signaling Technology); anti‐LDHA (C4B5) rabbit mAb (3582; Cell Signaling Technology); and anti‐HK2 (C64G5) rabbit mAb (2867; Cell Signaling Technology).

Pim1 siRNAs (si1: sense 5′‐GGAACAACAUUUACAACUCdTdT‐3′, antisense 5′‐GAGUUGUAAAUGUUGUUCCdTdT‐3′; si2: sense 5′‐GAUAUGGUGUGUGGAGAUA‐3′, antisense 5′‐ UAU‐CUCCACACACCAUAUC‐3′), and a negative control siRNA (Scramble: sense 5′‐CUUACGCUGAGUACUUCGAdTdT‐3′, antisense 5′‐ UCGAAGUACUCAGCGUAAGdTdT‐3′) were purchased from GenePharma (Shanghai, China). 2‐Deoxyglucose (2‐DG, Sigma Chemical Co., St Louis, MO, USA), A769662 and Compound C (Selleck Chemicals, Houston, TX, USA) were added to the medium as indicated.

2.10. Statistical analysis {#cas13562-sec-0012}
--------------------------

The chi‐squared‐test or Fisher\'s exact test was used to analyze the association between the clinicopathological features and Pim1 expression and gene copy numbers. The Kaplan‐Meier method with log‐rank test was used to analyze patients' survival curves. A Cox proportional hazards model was used to evaluate the associations between clinicopathological features and survival. Student\'s *t* test and one‐way ANOVA were used for analyzing statistical significance. Statistical analyses were carried out using SPSS software, version 20.0 (SPSS Inc., Chicago, IL, USA). *P* \< .05 was considered statistically significant.

3. RESULTS {#cas13562-sec-0013}
==========

3.1. Clinical information {#cas13562-sec-0014}
-------------------------

Specimens were collected from 296 patients (173 men and 123 women) with a median age of 57 years (range, 27‐81 years). Follow up ended on 31 Jan 2016, with a median follow‐up duration of 80 months (range, 1‐97 months). At the last follow up, 214 patients were still alive, and 82 had died. In total, 68 of the 248 patients experienced recurrence.

3.2. Pim1 is upregulated in CRC tissues {#cas13562-sec-0015}
---------------------------------------

First, we conducted IHC analysis in 296 patients with CRC to determine whether Pim1 expression was altered in cancer tissues. As shown in Figure [1](#cas13562-fig-0001){ref-type="fig"}A, Pim1 immunoreactivity was observed in both the nucleus and the cytoplasm of tumor cells. Pim1 was significantly upregulated in 81.8% (242 of 296) of primary cancer specimens and in 24.6% (35 of 142) of normal tissue specimens. qRT‐PCR and western blot assays were carried out to investigate the level of Pim1 in fresh tissue samples. Compared to those in normal mucosa, both Pim1 mRNA and protein levels were upregulated in cancer tissues (Figure [1](#cas13562-fig-0001){ref-type="fig"}B,C).

![Pim1 is highly expressed in colorectal cancer (CRC) tissues and predicts poor prognosis. A, Representative immunohistochemistry for Pim1 in normal colorectal epithelial and CRC tissues indicating cytoplasmic staining, nuclear staining or both. B, mRNA level of Pim1 in 72 CRC tissues and adjacent normal tissues detected by qRT‐PCR. C, Representative western blots showing Pim1 protein level. D,E, Kaplan‐Meier analysis of overall survival (OS) and disease‐free survival (DFS) for 296 CRC patients. Patients with positive Pim1 expression had poorer (D) OS and (E) DFS than patients with negative Pim1 expression](CAS-109-1468-g001){#cas13562-fig-0001}

3.3. Correlation of Pim1 levels with clinicopathological characteristics and survival of patients with CRC {#cas13562-sec-0016}
----------------------------------------------------------------------------------------------------------

Next, we determined the correlation between Pim1 expression and clinicopathological characteristics of CRC patients (Table [1](#cas13562-tbl-0001){ref-type="table-wrap"}). Pim1 expression was positively correlated with tumor size (*P* \< .01) and invasion depth (T stage, *P* = .018). Kaplan‐Meier curves with a log‐rank analysis showed a significant difference in OS and DFS among patients with different levels of Pim1 (Figure [1](#cas13562-fig-0001){ref-type="fig"}D,E). Patients with Pim1‐positive tumors had a significantly lower OS than patients with Pim1‐negative tumors (69.8% vs 83.3%). In univariate analysis, patients with Pim1‐positive tumors had markedly lower DFS and OS than those with Pim1‐negative tumors (DFS, HR 3.296 \[95% CI 1.400‐7.757\]; OS, HR 2.638 \[95% CI 1.231‐5.654\]) (Table [2](#cas13562-tbl-0002){ref-type="table-wrap"}). In addition, AJCC stage, T stage, N stage, and M stage were correlated with OS; and AJCC stage, T stage, and N stage were correlated with DFS. In multivariate analysis, Pim1 expression was not an independent prognostic factor for OS and DFS for CRC patients (Table [3](#cas13562-tbl-0003){ref-type="table-wrap"}). Collectively, these data suggest a potential promotive role of Pim1 in CRC progression.

###### 

Association between clinicopathological features of CRC patients and Pim1 expression

  Parameter                  n     Pim1 expression   *P*‐value                
  -------------------------- ----- ----------------- ------------ ----------- ----------------------------------------------
  Cases (n, %)               296   54 (18.2)         176 (59.5)   66 (22.3)   
  Age, years (n, %)                                                           
  \<57                       137   18 (13.1)         86 (62.8)    33 (24.1)   .106
  ≥57                        159   36 (22.6)         90 (56.6)    33 (20.8)   
  Gender (n, %)                                                               
  Male                       173   33 (19.1)         99 (57.2)    41 (23.7)   .646
  Female                     123   21 (17.1)         77 (62.6)    25 (20.3)   
  Tumor size (n, %)                                                           
  ≤4 cm                      123   37 (30.1)         65 (52.8)    21 (17.1)   \<.01[a](#cas13562-note-0043){ref-type="fn"}
  \>4 cm                     173   17 (9.8)          111 (64.2)   45 (26.0)   
  T stage (n, %)                                                              
  T1‐T3                      99    23 (23.2)         63 (63.6)    13 (13.1)   .018[a](#cas13562-note-0043){ref-type="fn"}
  T4                         197   31 (15.7)         113 (57.4)   53 (26.9)   
  N stage (n, %)                                                              
  N0                         122   27 (22.1)         73 (59.8)    22 (18.0)   .083
  N1                         94    19 (20.2)         56 (59.6)    19 (20.2)   
  N2                         80    8 (10.0)          47 (58.8)    25 (31.3)   
  M stage (n, %)                                                              
  M0                         248   48 (19.4)         148 (59.7)   52 (21.0)   .323
  M1                         48    6 (12.5)          28 (58.3)    14 (29.2)   
  AJCC stage (n, %)                                                           
  I                          24    4 (16.7)          17 (70.8)    3 (12.5)    .270
  II                         83    21 (25.3)         48 (57.8)    14 (16.9)   
  III                        141   23 (16.3)         83 (58.9)    35 (24.8)   
  IV                         48    6 (12.5)          28 (58.3)    14 (29.2)   
  Differentiation (n, %)                                                      
  High                       17    3 (17.6)          10 (58.8)    4 (23.5)    .119
  Moderate                   206   42 (20.4)         126 (61.2)   38 (18.4)   
  Low                        73    9 (12.3)          40 (54.8)    24 (32.9)   
  Vascular invasion (n, %)                                                    
  Yes                        90    15 (16.7)         54 (60.0)    21 (23.3)   .885
  No                         206   39 (18.9)         122 (59.2)   45 (21.8)   
  Ki‐67 index (n, %)                                                          
  Negative                   118   21 (17.8)         73 (61.9)    24 (20.3)   .760
  Positive                   178   33 (18.5)         103 (57.9)   42 (23.6)   

AJCC, American Joint Committee on Cancer; CRC, colorectal cancer.

*P* \<.05 is statistically significant.

John Wiley & Sons, Ltd

###### 

Univariate Cox proportional hazards model of CRC patients for OS and DFS

  Variable          OS                     DFS                                                                   
  ----------------- ---------------------- ----------------------------------------------- --------------------- -----------------------------------------------
  Pim1 expression   2.638 (1.231‐5.654)    .013[a](#cas13562-note-0005){ref-type="fn"}     3.296 (1.400‐7.757)   .006[a](#cas13562-note-0005){ref-type="fn"}
  AJCC stage        5.703 (3.941‐8.255)    \<.001[a](#cas13562-note-0005){ref-type="fn"}   3.421 (1.996‐5.865)   \<.001[a](#cas13562-note-0005){ref-type="fn"}
  T stage           2.988 (1.828‐4.882)    \<.001[a](#cas13562-note-0005){ref-type="fn"}   1.894 (1.279‐2.804)   .001[a](#cas13562-note-0005){ref-type="fn"}
  N stage           2.457 (1.850‐3.263)    \<.001[a](#cas13562-note-0005){ref-type="fn"}   2.026 (1.509‐2.719)   \<.001[a](#cas13562-note-0005){ref-type="fn"}
  M stage           10.687 (6.744‐16.94)   \<.001[a](#cas13562-note-0005){ref-type="fn"}   1.092 (0.848‐1.408)   .494
  Ki‐67 index       0.983 (0.785‐1.231)    .882                                            0.848 (0.535‐1.345)   .485

AJCC, American Joint Committee on Cancer; CRC, colorectal cancer; DFS, disease‐free survival; HR, hazard ratio; OS, overall survival.

*P *\< .05 is statistically significant.

John Wiley & Sons, Ltd

###### 

Multivariate Cox proportional hazards model of CRC patients for OS and DFS

  Variable          OS                    DFS                                                                   
  ----------------- --------------------- ----------------------------------------------- --------------------- ---------------------------------------------
  Pim1 expression   1.511 (0.697‐3.276)   .295                                            2.275 (0.949‐5.453)   .065
  AJCC stage        4.626 (3.092‐6.922)   \<.001[a](#cas13562-note-0007){ref-type="fn"}   2.464 (1.137‐5.339)   .022[a](#cas13562-note-0007){ref-type="fn"}
  T stage           1.856 (1.132‐3.044)   .014[a](#cas13562-note-0007){ref-type="fn"}     1.451 (0.984‐2.141)   .061
  N stage           1.245 (0.901‐1.718)   .184                                            1.249 (0.797‐1.958)   .333
  Ki‐67 index       1.113 (0.887‐1.396)   .354                                            1.203 (0.929‐1.559)   .161

AJCC, American Joint Committee on Cancer; CRC, colorectal cancer; DFS, disease‐free survival; HR, hazard ratio; OS, overall survival.

*P *\< .05 is statistically significant.

John Wiley & Sons, Ltd

3.4. Pim1 is upregulated in CRC as a result of glucose deprivation by AMPK signaling {#cas13562-sec-0017}
------------------------------------------------------------------------------------

To determine whether glucose deprivation influences Pim1 expression, CRC cells were cultured with various concentrations of glucose. Pim1 mRNA (Figure [2](#cas13562-fig-0002){ref-type="fig"}A) and protein (Figure [2](#cas13562-fig-0002){ref-type="fig"}B) expression was markedly increased in response to glucose deprivation (0 mmol/L) in RKO, HCT116, LOVO and HT29 cells. In addition, this glucose deprivation‐induced overexpression of Pim1 was reverted by culture in complete medium with 25 mmol/L glucose (Figure [2](#cas13562-fig-0002){ref-type="fig"}A,B). AMPK is known as an intracellular energy sensor, and the Thr172 phosphorylated form of AMPK indicates the severity of glucose restriction.[3](#cas13562-bib-0003){ref-type="ref"} Our results showed that phosphorylated AMPK and Pim1 protein expression correspondingly increased in CRC cells (Figure [2](#cas13562-fig-0002){ref-type="fig"}B), suggesting that AMPK may act as a mediator of the response of Pim1 under glucose deprivation conditions. In addition, treatment of A769662 (an AMPK activator) induced Pim1 expression (Figure [2](#cas13562-fig-0002){ref-type="fig"}C), whereas AMPK inactivation by compound C (an AMPK inhibitor) treatment significantly attenuated glucose deprivation‐induced Pim1 expression (Figure [2](#cas13562-fig-0002){ref-type="fig"}D). Taken together, these findings suggest that Pim1 is a gene that responds to glucose deprivation at least partly through the AMPK pathway.

![Pim1 is upregulated by glucose deprivation through AMP‐activated protein kinase (AMPK). A,B, Colorectal cancer cells were cultured in medium with 0 or 25 mmol/L glucose for 24 h or rescued in complete medium with 25 mmol/L glucose after incubation with glucose‐free medium for another 24 h and then subjected to (A) qRT‐PCR or (B) western blot analysis. C, Pim1 expression was detected after HCT116 cells were treated with 100 μm A769662. D, Pim1 expression was detected after HCT116 cells were treated with 20 μmol/L Compound C in 25 or 0 mmol/L glucose‐containing medium for 24 h](CAS-109-1468-g002){#cas13562-fig-0002}

3.5. Determination of the efficiency of Pim1 overexpression and knockdown {#cas13562-sec-0018}
-------------------------------------------------------------------------

Baseline expression of Pim1 was examined in 8 CRC cancer cell lines, including HCT116, SW1116, RKO, SW620, LOVO, HT29, SW480 and Caco2, by both qRT‐PCR and western blotting (Figure [3](#cas13562-fig-0003){ref-type="fig"}A,B). Pim1 was expressed in all 8 CRC cell lines, and its expression was relatively lower in HT29 cells and relatively higher in RKO and LOVO cells. Thus, both RKO and LOVO cells were transfected for 48 hours with siRNAs against Pim1, and HT29 cells were transfected with pc3.1‐Pim1, followed by western blotting and qRT‐PCR. Pim1 levels were decreased in both protein and mRNA levels in RKO and LOVO cells transfected with siRNA (Figure [3](#cas13562-fig-0003){ref-type="fig"}C,D). However, the mRNA and protein levels of Pim1 were significantly higher in pc3.1‐Pim1‐transfected HT29 cells than in the vector‐transfected counterparts (Figure [3](#cas13562-fig-0003){ref-type="fig"}C,D).

![Efficiency of overexpression and knockdown of Pim1 in colorectal cancer (CRC). Baseline (A) mRNA and (B) protein expression of Pim1 in 8 CRC cell lines. C, mRNA and (D) protein levels of Pim1 detected by qRT‐PCR or western blotting, respectively, in RKO and LOVO cells transfected with siRNAs and in HT29 cells transfected with pc3.1‐Pim1](CAS-109-1468-g003){#cas13562-fig-0003}

3.6. Pim1 mediates cell proliferation in vitro and tumorigenicity in vivo {#cas13562-sec-0019}
-------------------------------------------------------------------------

To investigate the effect of Pim1 on tumor cell proliferation, we conducted CCK8 assays. In RKO and LOVO cells, knockdown of Pim1 by siRNA effectively inhibited cell proliferation (Figure [4](#cas13562-fig-0004){ref-type="fig"}A). In contrast, growth of Pim1‐overexpressing HT29 cells was significantly higher than that of control HT29 cells (Figure [4](#cas13562-fig-0004){ref-type="fig"}A). Colony formation assay showed that compared with control treatment, Pim1 knockdown inhibited colony formation in RKO and LOVO cells, whereas Pim1 overexpression promoted colony formation (Figure [4](#cas13562-fig-0004){ref-type="fig"}B).

![Pim1 promotes colorectal cancer cell proliferation in vitro and in vivo. A, CCK8 assays showed proliferative capacity of indicated cells. B, Colony formation assays showed clonogenicity of indicated cells. C, Nude mouse xenograft models showing that tumors formed by RKO‐shPim1 cells had lower growth rates and weight than tumors formed by RKO‐shNC cells (\**P* \< .05). Representative images of tumors in nude mice (lower). D, Representative images of immunohistochemistry staining for Ki‐67 and Pim1 (upper) and tumors formed by RKO‐shPim1 cells showed lower Ki‐67 index (lower). Sc, scramble. \* Indicates *P* \< .05](CAS-109-1468-g004){#cas13562-fig-0004}

To further validate the effects observed in vivo, we s.c. injected RKO‐shPim1 and control (RKO‐shNC) cells into nude mice. Consistent with our results in vitro, volumes and weights of tumors formed by RKO‐shPim1 cells were significantly lower than those of tumors formed by RKO‐shNC cells (Figure [4](#cas13562-fig-0004){ref-type="fig"}C). Ki‐67 index was also lower in the Pim1 knockdown groups than in the control groups (Figure [4](#cas13562-fig-0004){ref-type="fig"}D). Therefore, Pim1 promotes CRC tumorigenesis both in vitro and in vivo.

3.7. Altered Pim1 expression affects the Warburg effect in CRC cells {#cas13562-sec-0020}
--------------------------------------------------------------------

Next, we attempted to verify whether Pim1 promotes the Warburg effect in CRC cells. Pim1 knockdown decreased glucose uptake and lactate production in cells, whereas Pim1 overexpression markedly increased these phenomena (Figure [5](#cas13562-fig-0005){ref-type="fig"}A,C). In addition, mRNA (Figure [5](#cas13562-fig-0005){ref-type="fig"}B,D) and protein (Figure [5](#cas13562-fig-0005){ref-type="fig"}E,F) levels of HK2 and LDHA, which are key enzymes responsible for the Warburg effect, were positively regulated by Pim1 expression.

![Pim1 facilitates the Warburg effect in colorectal cancer cells. A, Glucose uptake and lactate production in indicated cells 24 h after transfection (\**P* \< .05). B, Knockdown of Pim1 decreased hexokinase 2 (HK2) and lactate dehydrogenase A (LDHA) mRNA levels (\**P* \< .05). C, Pim1 overexpression facilitated the Warburg effect in HT29 cells and (D) increased HK2 and LDHA mRNA levels (\**P* \< .05). E, Knockdown of Pim1 decreased HK2 and LDHA protein levels. F, Pim1 overexpression increased HK2 and LDHA protein levels. G, Pim1 H score based on immunohistochemistry was positively correlated with maximum standard uptake value (SUVmax). H, Relationship of Pim1 with HK2 and LDHA was analyzed using GEPIA (<http://gepia.cancer-pku.cn/>). Sc, scramble](CAS-109-1468-g005){#cas13562-fig-0005}

SUVmax was used as an index of ^18^F‐FDG accumulation. To investigate the relationship between Pim1 expression and metabolism in CRC cells, we analyzed the relationship between Pim1 H scores (based on IHC) and SUVmax in 37 CRC patients. Pim1 H score was positively correlated with SUVmax (Figure [5](#cas13562-fig-0005){ref-type="fig"}G, *R* ^2^ = 0.2836, *P* = .0007), suggesting that Pim1 expression was correlated with glucose uptake. Bioinformatics analysis using GEPIA (<http://gepia.cancer-pku.cn/>) further verified that Pim1 expression was positively related to HK2 and LDHA expression in CRC patients (Figure [5](#cas13562-fig-0005){ref-type="fig"}H), indicating that Pim1 enhances the Warburg effect in CRC.

3.8. Pim1 ensures CRC cell survival and resists glucose deprivation by the Warburg effect {#cas13562-sec-0021}
-----------------------------------------------------------------------------------------

Finally, we evaluated cell viability under glucose deprivation conditions by CCK8 assay. Knockdown of Pim1 reduced cell number in the setting of glucose deprivation (Figure [6](#cas13562-fig-0006){ref-type="fig"}A,B). Likewise, Pim1 overexpression increased HT29 cell survival under glucose deprivation conditions (Figure [6](#cas13562-fig-0006){ref-type="fig"}C). However, when the Warburg effect was blocked by 2‐deoxyglucose (2‐DG, 5 mmol/L), Pim1‐induced cell tolerance for glucose starvation was at least partially attenuated (Figure [6](#cas13562-fig-0006){ref-type="fig"}C). Furthermore, CCK8 assays showed that 2‐DG could partially abolish Pim1 overexpression‐induced cell proliferation when cells were cultured with glucose (Figure [6](#cas13562-fig-0006){ref-type="fig"}D). Collectively, these results suggested that Pim1 ensures CRC cell survival and resists metabolic stress by the Warburg effect.

![Pim1 ensures colorectal cancer cell survival during glucose deprivation. A, RKO and (B) LOVO transfected with Pim1 siRNAs or scramble siRNA (Sc) were cultured in glucose‐free medium for different numbers of days as indicated, and then subjected to CCK8 assays (\**P* \< .05). C, Pim1 overexpression increased HT29 cell survival under glucose deprivation conditions, but was then partially abolished by 2‐deoxyglucose (2‐DG, 5 mmol/L). D, 2‐DG attenuated Pim1‐induced tumor proliferation when indicated cells were cultured in medium containing glucose (\**P* \< .05)](CAS-109-1468-g006){#cas13562-fig-0006}

4. DISCUSSION {#cas13562-sec-0022}
=============

Metabolic stress is considered a common impediment to tumor growth; however, it remains unclear how cancer cells overcome metabolic stress to keep growing.[3](#cas13562-bib-0003){ref-type="ref"} Our study showed that Pim1 was upregulated by AMPK signaling in response to glucose deprivation, indicating that Pim1 acts as an oncogene that is responsive to glucose deprivation. Clinical observations showed that Pim1 overexpression in CRC tissues was a predictor of prognosis and that Pim1 expression had a positive relationship with ^18^F‐FDG uptake. Further in vitro experiments indicated that Pim1 promoted the Warburg effect and that Pim1 expression was positively correlated with HK2 and LDHA expression. Finally, Pim1‐silenced cells were more vulnerable to glucose starvation, and Pim1‐induced tumor proliferation or tolerance to glucose starvation was attenuated by blocking of the Warburg effect. These findings provided evidence that Pim1 is overexpressed in CRC under glucose deprivation conditions and that it ameliorates metabolic stress by promoting the Warburg effect, thereby enhancing CRC progression (Figure [7](#cas13562-fig-0007){ref-type="fig"}).

![Pim1 facilitates the Warburg effect in colorectal cancer (CRC) cells. Diagram summarizing the role of Pim1 in metabolic regulation in CRC. AMP‐activated protein kinase (AMPK) is activated by phosphorylation under glucose deprivation, thus upregulating Pim1 expression. Pim1 increases the expression of several glycolytic enzymes, including hexokinase 2 (HK2) and lactate dehydrogenase A (LDHA). Furthermore, the Warburg effect is enhanced in a compensatory way to promote CRC cell survival and proliferation. These findings explain why Pim1 expression increases with the progression of CRC and how Pim1 promotes tumor malignancy](CAS-109-1468-g007){#cas13562-fig-0007}

Oncogenic PIM1 is a constitutively active serine‐threonine kinase. Pim1 can promote cell cycle progression by phosphorylating CDC25A, CDC25C, p21cip1, p27kip1, and c‐TAK1.[14](#cas13562-bib-0014){ref-type="ref"}, [25](#cas13562-bib-0025){ref-type="ref"}, [26](#cas13562-bib-0026){ref-type="ref"}, [27](#cas13562-bib-0027){ref-type="ref"}, [28](#cas13562-bib-0028){ref-type="ref"} In addition to its essential roles in the cell cycle, Pim1 is involved in proliferation, migration, apoptosis, cell death, tumor growth, and chemotherapy response in cancer cells.[16](#cas13562-bib-0016){ref-type="ref"}, [29](#cas13562-bib-0029){ref-type="ref"}, [30](#cas13562-bib-0030){ref-type="ref"} Pim1 is overexpressed in many types of cancer cells, including hepatocellular cancer, prostate cancer, glioblastoma, lung cancer, breast cancer and CRC, and its overexpression is associated with tumor development and progression.[13](#cas13562-bib-0013){ref-type="ref"}, [15](#cas13562-bib-0015){ref-type="ref"}, [16](#cas13562-bib-0016){ref-type="ref"}, [17](#cas13562-bib-0017){ref-type="ref"}, [18](#cas13562-bib-0018){ref-type="ref"}, [19](#cas13562-bib-0019){ref-type="ref"} In the present study, we used CRC TMA containing 296 CRC patient samples and 72 fresh CRC samples. Based on our results, Pim1 was overexpressed in CRC tissues relative to that in adjacent normal tissues, and Pim1 overexpression was correlated with tumor size and invasion depth. Despite the critical role of Pim1 in cancer development and progression, there is little evidence regarding the function of Pim1 in cancer metabolism, especially in CRC.

Cancer metabolism is an important link between the tumor microenvironment and tumor progression.[31](#cas13562-bib-0031){ref-type="ref"} Hirayama A et al[1](#cas13562-bib-0001){ref-type="ref"} reported that CRC tumor tissues have much lower glucose and higher lactate levels than do normal tissues, indicating that metabolic stress plays an important role in colorectal carcinogenesis. In the present study, AMPK was activated under glucose deprivation and, in turn, upregulated Pim1 expression, suggesting that Pim1 upregulation in response to glucose deprivation may be a compensatory mechanism by which CRC cells overcome stress. For cancer cells, glycolysis is an important mechanism for the generation of energy and sustaining proliferation and aggressive features.[13](#cas13562-bib-0013){ref-type="ref"} Even with normal oxygen concentrations, cancer cells consume more glucose and produce more lactate than do normal cells.[32](#cas13562-bib-0032){ref-type="ref"} One possible explanation for this phenomenon is the overexpression of glucose transporters and enzymes in the glycolytic pathway resulting from oncogene activation.[23](#cas13562-bib-0023){ref-type="ref"}, [33](#cas13562-bib-0033){ref-type="ref"} In the present study, we found that altered Pim1 expression influenced glucose consumption and lactate production by regulating the expression of HK2 and LDHA. In addition, Pim1 expression was positively correlated with HK2 and LDHA expression in CRC tissues.

It is well established that Pim1 is closely linked with c‐myc. Jongchan Kim et alreported that Pim1 promotes tumorigenicity at least in part by enhancing c‐MYC transcriptional activity in prostate cancer.[34](#cas13562-bib-0034){ref-type="ref"} Coexpression of both Pim1 and c‐myc has been observed in prostate cancer and triple‐negative breast cancer.[14](#cas13562-bib-0014){ref-type="ref"}, [35](#cas13562-bib-0035){ref-type="ref"} The first identified glucose metabolism‐associated gene that is directly regulated by c‐myc is LDHA,[36](#cas13562-bib-0036){ref-type="ref"}, [37](#cas13562-bib-0037){ref-type="ref"} and the subsequently identified genes are GLUT1 and HK2.[38](#cas13562-bib-0038){ref-type="ref"}, [39](#cas13562-bib-0039){ref-type="ref"} Knockdown of Pim1 has also been reported to reduce glycolysis in hepatocellular carcinoma by targeting the PI3K/AKT pathway.[13](#cas13562-bib-0013){ref-type="ref"} These findings highlight the possible role of Pim1 in cancer metabolism.

In summary, for the first time, the present study provided critical insights into the role of Pim1 in CRC metabolism. Pim1 was upregulated in CRC tissues under conditions of glucose deprivation, which facilitated the Warburg effect in a compensatory manner to promote CRC cell survival and proliferation. Our results thus indicate a diagnostic and therapeutic role of Pim1 in CRC.
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